Piper Jaffray Initiates Coverage of Trovagene with an Overweight Rating

Feb 17, 2015

|

NEW YORK (GenomeWeb) – Piper Jaffray today initiated coverage of molecular cancer diagnostic firm Trovagene with an Overweight rating and a $6.25 price target.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

To Control the Spread

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

More to Do

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

This Week in PLOS

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

'Follow Me to Maryland'

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.

Main menu